Global Antineoplastic Tenders and GPN from across the Globe

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Nilotinib (Atc Code: L01ea03).

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Rituximab (Atc Code: L01fa01).

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Golimumab (Atc Code: L04ab06).

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for Drugs with the Active Ingredient Octreotide, in a Dosage Form with Delayed Release Behavior Atc Code: H01cb02

Medicinal Products

Medicinal Products

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Medicines with the Active Ingredient Glatiramer Acetate (Atc Code: L03ax13), with the Exception o...

Dynamic Acquisition System for Class L Drugs (18.07 Anti-opling & Immunomodulators) and Class N (18.09 Nervous System) of Gcs Pharma Hauts-de-france

Antineoplastic Drugs

Antineoplastic Drugs